Alto Neuroscience (ANRO) Cash from Financing Activities (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Cash from Financing Activities data on file, last reported at $114.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1159.35% year-over-year to $114.9 million; the trailing twelve-month figure through Mar 2026 stood at $165.9 million (up 1517.04% YoY), and the FY2025 full-year result was $60.1 million, down 55.72% from the prior year.
• Cash from Financing Activities rose to $114.9 million in Q1 2026, from $50.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $134.6 million in Q1 2024 to a low of -$234000.0 in Q2 2024.
• A 4-year average of $29.1 million and a median of $1.3 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 358.82% in 2024 and jumped 102318.37% in 2025, its largest moves.
• Tracing ANRO's Cash from Financing Activities over 4 years: stood at $43.1 million in 2023, then plunged by 99.89% to $49000.0 in 2024, then jumped by 102318.37% to $50.2 million in 2025, then jumped by 129.03% to $114.9 million in 2026.
• Business Quant data shows ANRO's Cash from Financing Activities at $114.9 million in Q1 2026, $50.2 million in Q4 2025, and $153000.0 in Q3 2025.